|Publication Type||Journal Article|
|Year of Publication||2017|
|Authors||Goldstein, JT, Berger, AC, Shih, J, Duke, FF, Furst, L, Kwiatkowski, DJ, Cherniack, AD, Meyerson, M, Strathdee, CA|
|Date Published||2017 Sep 18|
The PPARG gene encoding the nuclear receptor PPAR-gamma is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene which encodes the heterodimeric partner of PPAR-gamma. Here we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer.
|Alternate Journal||Cancer Res.|
|Grant List||R35 CA197568 / CA / NCI NIH HHS / United States|